We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » ICH: Drugmaker Risk-Benefit Reports Should Highlights Benefits
ICH: Drugmaker Risk-Benefit Reports Should Highlights Benefits
March 8, 2012
A new International Conference on Harmonisation (ICH) report seeks streamlined postmarket safety filings for drugmakers while adding a new feature to highlight products’ benefits.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor